TOKYO -- Takeda Pharmaceutical will sell five prescription products to China's Hasten Biopharmaceutic in a $322 million deal as Japan's top drugmaker continues to slash debt from its acquisition of Ireland-based peer Shire.
Pharmaceuticals
Takeda sells 5 prescription drugs to China's Hasten for $322m
Blood pressure treatment Ebrantil part of Japanese company's latest asset sale
Japan's Takeda will sell off prescription drugs available in China, including the Ebrantil blood pressure reducer. (Photo by Nobuyoshi Shioda)
Read Next
Latest on Pharmaceuticals
